<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02802306</url>
  </required_header>
  <id_info>
    <org_study_id>CA 0135</org_study_id>
    <nct_id>NCT02802306</nct_id>
  </id_info>
  <brief_title>Tack Optimized Drug Coated Balloon Angioplasty Study of the Tack Endovascular System™ in Femoropoliteal Arteries</brief_title>
  <acronym>TOBA III</acronym>
  <official_title>Tack Optimized Drug Coated Balloon Angioplasty in the Superficial Femoral and Proximal Popliteal Arteries Using the Tack Endovascular System™</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intact Vascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intact Vascular</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an Outside the United States, post-CE Mark, multi-center, single-arm, non-blinded
      study designed to investigate the safety and efficacy of the Tack Endovascular System. This
      study will evaluate subjects with PAD who receive PTA (with a drug-coated balloon (DCB)) in
      the SFA and in popliteal arteries, ranging in diameter from 2.5mm to 6.0mm and lesion lengths
      of ≥20mm and ≤150mm, and have a resulting dissection(s) type(s) A through F. TOBA III will
      also evaluate the safety and efficacy of the device when used to treat a sub-group presenting
      with longer lesions of &gt;150mm and ≤250mm.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety - Freedom from the occurrence of any new-onset major adverse event(s)</measure>
    <time_frame>30 days</time_frame>
    <description>Freedom from the occurrence of any new-onset major adverse event(s) (MAEs) defined as index limb amputation (above the ankle), CEC adjudicated clinically-driven target lesion revascularization (CD-TLR), or all-cause death at 30 days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy</measure>
    <time_frame>12 months</time_frame>
    <description>Primary patency defined as freedom from CEC adjudicated clinically driven target lesion revascularization (CD-TLR) and freedom from core lab adjudicated duplex ultrasound derived binary restenosis at 12 months (defined as PSVR &gt;2.5:1).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>Tack Implant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Implantation of a Tack implant using the Intact Vascular Tack Endovascular System for the repair of post DCB-angioplasty dissections.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Tack Endovascular System</intervention_name>
    <description>Repair of post-PTA dissections using the Intact Vascular Tack Endovascular System</description>
    <arm_group_label>Tack Implant</arm_group_label>
    <other_name>Post-PTA Dissection Repair Implant</other_name>
    <other_name>Tack Implant</other_name>
    <other_name>Tack Dissection Repair Device</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must meet all of the following inclusion criteria to be eligible for
             enrollment:

               1. Male or non-pregnant Female ≥ 18 years of age at the time of consent

               2. Female subjects of childbearing potential must have a negative pregnancy test
                  prior to treatment and must use some form of contraception through the duration
                  of the study

               3. Target limb requires no additional treatment aside from the target lesion and the
                  iliac artery(ies) during the index procedure

               4. Subject or has been informed of and understands the nature of the study and
                  provides signed informed consent to participate in the study. If the subject
                  possesses the ability to understand and provide informed consent but due to
                  physical inability, the subject cannot sign the ICF, an impartial witness may
                  sign on behalf of the subject

               5. Willing to comply with all required follow-up visits

               6. Rutherford Classification 2, 3 or 4

               7. Estimated life expectancy &gt;1 year

               8. Eligible for standard surgical repair, if necessary

               9. Subject is ambulatory (assistive devices such as a cane or walker is acceptable

        Exclusion Criteria:

          -  Subject must NOT meet any of the following exclusion criteria to be eligible for
             enrollment:

               1. Rutherford Classification 0, 1, 5 or 6

               2. Is pregnant or refuses to use contraception through the duration of the study

               3. Previous infrainguinal bypass graft in the target limb

               4. Planned amputation on the target limb

               5. Systemic infection or infection within the target limb and/or immunocompromised

               6. Endovascular or surgical procedure (not including diagnostic procedures) on the
                  target limb within 30 days prior to or within 30 days after the index procedure

               7. Endovascular or surgical procedure (not including diagnostic procedures) on the
                  non-target limb within 14 days prior to the index procedure or planned procedure
                  within 30 days after the index procedure

               8. Prior coronary artery bypass graft (CABG) or percutaneous coronary intervention
                  (PCI) procedure within 30 days prior to the index procedure or planned CABG/PCI
                  within 30 days after the index procedure

               9. Any other previous or planned surgical or endovascular procedure (not including
                  diagnostic procedures) within 14 days prior to or 30 days post index procedure

              10. Planned atherectomy, cryoplasty, stenting or any other treatment (with the
                  exception of a crossing device) of the target lesion other than PTA during the
                  index procedure

              11. Known coagulopathy, hypercoagulable state, bleeding diathesis, other blood
                  disorder, or a platelet count less than 80,000/microliter or greater than
                  500,000/microliter

              12. Known hypersensitivity or allergy to antiplatelet or anticoagulant therapy

              13. Myocardial infarction within 30 days prior to enrollment

              14. History of stroke within 90 days prior to enrollment

              15. Serum creatinine of &gt;2.5 mg/dL

              16. Requires treatment of tibial or outflow vessels at the index procedure, which
                  include the P2 and P3 segments of the popliteal artery and the tibioperoneal
                  vessels

              17. Known hypersensitivity or contraindication to nickel-titanium alloy (Nitinol)

              18. Participating in another ongoing investigational clinical trial that has not
                  completed its primary endpoint

              19. Has other comorbidities that, in the opinion of the investigator, would preclude
                  them from receiving this treatment and/or participating in study-required
                  follow-up assessments

              20. Known hypersensitivity or allergy to contrast agents that cannot be medically
                  managed

              21. Thrombolysis of the target vessel within 72 hours prior to the index procedure,
                  where complete resolution of the thrombus was not achieved
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marianne Brodmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University Hospital Graz</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joseph C Griffin, III</last_name>
    <phone>484-253-1043</phone>
    <email>jgriffin@intactvascular.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital AKH Vienna</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florian Wolf, MD</last_name>
      <phone>43 1 40400 58020</phone>
    </contact>
    <contact_backup>
      <last_name>Johanna Moyses</last_name>
      <phone>43 1 40400 58900</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Imelda Hosptial</name>
      <address>
        <city>Bonheiden</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Peeters, Dr.</last_name>
      <phone>32 15 50 6182</phone>
    </contact>
    <contact_backup>
      <last_name>Wendy Janssens</last_name>
      <phone>32 15 50 6182</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>A.Z. St. Blasius Hospital</name>
      <address>
        <city>Dendermonde</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Bosiers, MD</last_name>
      <phone>32 052 25 27 35</phone>
    </contact>
    <contact_backup>
      <last_name>Jereon Wauters</last_name>
      <phone>32 52 25 28 22</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Karolinen-Hospital Klinik für Angiologie Arnsberg Clinic</name>
      <address>
        <city>Arnsberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Lichtenberg, MD</last_name>
      <phone>49 2932 952 1271</phone>
    </contact>
    <contact_backup>
      <last_name>Martin Kuhmann, MD</last_name>
      <phone>49 0932 952 1271</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitats-Herzzentrum Freiburg-Bad Krozingen Klinik fur Kardiologie und Angiologie lI</name>
      <address>
        <city>Bad Krozingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Zeller, Prof. Dr.</last_name>
      <phone>49 7633 402 4973</phone>
    </contact>
    <contact_backup>
      <last_name>Verena Zahringer</last_name>
      <phone>49 7633 402 4978</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Franziskus-Hospital Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Klaus Brechtel, MD</last_name>
      <phone>(49) 3032 29 13 190</phone>
    </contact>
    <contact_backup>
      <last_name>Richard Wegner</last_name>
      <phone>(49) 3026 38 34 12</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik II Fürst Stirum Klinik Bruchsal</name>
      <address>
        <city>Bruchsal</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Andrassy, MD</last_name>
      <phone>49 7251 708 58302</phone>
    </contact>
    <contact_backup>
      <last_name>Manuela Scherer-Stolz</last_name>
      <phone>49 7251 708 58506</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Norbert Weiss, MD</last_name>
      <phone>(49) 351 458 3659</phone>
    </contact>
    <contact_backup>
      <last_name>Elke Festerling</last_name>
      <phone>(49) 351 458 3156</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik St. Georg Herz-, Gefäß- und Therapiezentrum, Abt. Klinische und Interventionelle Angiologie</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sigrid Nikol, Prof. Dr.</last_name>
      <phone>(49) 40 1818 85 2401</phone>
    </contact>
    <contact_backup>
      <last_name>Katrin Borchers</last_name>
      <phone>(49) 40 1818 85 2527</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Center for Cardiology &amp; Vascular Intervention</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sebastian Sixt, Dr.</last_name>
      <phone>49 40 889 009 889</phone>
    </contact>
    <contact_backup>
      <last_name>Kerstin Flint</last_name>
      <phone>49 40 889 009 889</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Westküstenklinikum Heide</name>
      <address>
        <city>Heide</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Wissgott, MD</last_name>
      <phone>(49) 481-785-2431</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herz und Gefäßzentrum im Klinikverbund Oberallgäu-Kempten</name>
      <address>
        <city>Immenstadt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wulf Ito, MD</last_name>
      <phone>49 8323 910 8701</phone>
    </contact>
    <contact_backup>
      <last_name>Jacqueline Fielder</last_name>
      <phone>49 8323 910 8909</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Klinikum Karlsbad Langensteinbach</name>
      <address>
        <city>Karlsbad</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erwin Blessing, Prof. Dr.</last_name>
      <phone>49 7202 61 3340</phone>
    </contact>
    <contact_backup>
      <last_name>Bernd Kroeg</last_name>
      <phone>49 7202 61 7216</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Leipzig</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dierk Scheinert, MD</last_name>
      <phone>(49) 341 9718770</phone>
    </contact>
    <contact_backup>
      <last_name>Janin Lenzer</last_name>
      <phone>(49) 341 9718774</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Mainz II Medizinische Klinik und Poliklinik, Angiologie</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Espinola-Klein, Prof. Dr.</last_name>
      <phone>(49) 6131 17 39 60</phone>
    </contact>
    <contact_backup>
      <last_name>Gerhard Weisser</last_name>
      <phone>(49) 6131 17 39 60</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Cantonal Hospital Lucerne Division of Angiology</name>
      <address>
        <city>Lucerne</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Banyai, Dr.</last_name>
      <phone>41 41 205 22 39</phone>
    </contact>
    <contact_backup>
      <last_name>Virginia Justi</last_name>
      <phone>41 41 205 52 30</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Ospedale Regionale di Lugano - Civico e Italiana Civico</name>
      <address>
        <city>Lugano</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jos Van den Berg, PD Dr.</last_name>
      <phone>41 (0) 91 811 60 72</phone>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2016</study_first_submitted>
  <study_first_submitted_qc>June 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2016</study_first_posted>
  <last_update_submitted>January 24, 2018</last_update_submitted>
  <last_update_submitted_qc>January 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Angioplasty</keyword>
  <keyword>Peripheral Artery Disease</keyword>
  <keyword>PAD</keyword>
  <keyword>Lesion</keyword>
  <keyword>Claudication</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

